Your browser doesn't support javascript.
loading
International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma.
Lee, Anne W; Ng, Wai Tong; Pan, Jian Ji; Chiang, Chi-Leung; Poh, Sharon S; Choi, Horace C; Ahn, Yong Chan; AlHussain, Hussain; Corry, June; Grau, Cai; Grégoire, Vincent; Harrington, Kevin J; Hu, Chao Su; Kwong, Dora L; Langendijk, Johannes A; Le, Quynh Thu; Lee, Nancy Y; Lin, Jin Ching; Lu, Tai Xiang; Mendenhall, William M; O'Sullivan, Brian; Ozyar, Enis; Peters, Lester J; Rosenthal, David I; Sanguineti, Giuseppe; Soong, Yoke Lim; Tao, Yungan; Yom, Sue S; Wee, Joseph T.
Affiliation
  • Lee AW; Department of Clinical Oncology, University of Hong Kong Shenzhen Hospital and University of Hong Kong, China.
  • Ng WT; Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong.
  • Pan JJ; Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China.
  • Chiang CL; Department of Clinical Oncology, University of Hong Kong Shenzhen Hospital and University of Hong Kong, China.
  • Poh SS; Division of Radiation Oncology, National Cancer Centre Singapore, Oncology ACP, Duke-NUS Medical School, Singapore.
  • Choi HC; Department of Clinical Oncology, University of Hong Kong, Hong Kong.
  • Ahn YC; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • AlHussain H; Department of Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Corry J; Radiation Oncology, GenesisCare, St. Vincent's Hospital, Melbourne, Victoria, Australia.
  • Grau C; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Grégoire V; Center for Molecular Imaging, Oncology and Radiotherapy, Université Catholique de Louvain, Brussels, Belgium and Department of Radiation Oncology, Centre Léon Bérard, Lyon, France.
  • Harrington KJ; The Royal Marsden/The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre, London, UK.
  • Hu CS; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Kwong DL; Department of Clinical Oncology, University of Hong Kong and Queen Mary Hospital, Hong Kong.
  • Langendijk JA; Department of Radiotherapy, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
  • Le QT; Department of Radiation Oncology, Stanford University, NRG Oncology and Head and Neck Cancer International Group, California.
  • Lee NY; Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York.
  • Lin JC; Department of Radiation Oncology, Taichung Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan.
  • Lu TX; Department of Radiation Oncology, Cancer Center of Sun Yat-Sen University, Guangzhou, China.
  • Mendenhall WM; Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida.
  • O'Sullivan B; Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Canada.
  • Ozyar E; Department of Radiation Oncology, Acibadem University School of Medicine, Istanbul, Turkey.
  • Peters LJ; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Rosenthal DI; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sanguineti G; Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Soong YL; Division of Radiation Oncology, National Cancer Centre Singapore, Oncology ACP, Duke-NUS Medical School, Singapore.
  • Tao Y; Department of Radiation Oncology, Institut Gustave Roussy, Paris-Saclay University, Villejuif, France.
  • Yom SS; Department of Radiation Oncology, University of California-San Francisco, San Francisco, California.
  • Wee JT; Division of Radiation Oncology, National Cancer Centre Singapore, Oncology ACP, Duke-NUS Medical School, Singapore. Electronic address: joseph.wee.t.s@singhealth.com.sg.
Int J Radiat Oncol Biol Phys ; 105(3): 567-580, 2019 11 01.
Article in En | MEDLINE | ID: mdl-31276776
ABSTRACT

PURPOSE:

The treatment of nasopharyngeal carcinoma requires high radiation doses. The balance of the risks of local recurrence owing to inadequate tumor coverage versus the potential damage to the adjacent organs at risk (OARs) is of critical importance. With advancements in technology, high target conformality is possible. Nonetheless, to achieve the best possible dose distribution, optimal setting of dose targets and dose prioritization for tumor volumes and various OARs is fundamental. Radiation doses should always be guided by the As Low As Reasonably Practicable principle. There are marked variations in practice. This study aimed to develop a guideline to serve as a global practical reference. METHODS AND MATERIALS A literature search on dose tolerances and normal-tissue complications after treatment for nasopharyngeal carcinoma was conducted. In addition, published guidelines and protocols on dose prioritization and constraints were reviewed. A text document and preliminary set of variants was circulated to a panel of international experts with publications or extensive experience in the field. An anonymized voting process was conducted to rank the proposed variants. A summary of the initial voting and different opinions expressed by members were then recirculated to the whole panel for review and reconsideration. Based on the comments of the panel, a refined second proposal was recirculated to the same panel. The current guideline was based on majority voting after repeated iteration for final agreement.

RESULTS:

Variation in opinion among international experts was repeatedly iterated to develop a guideline describing appropriate dose prioritization and constraints. The percentage of final agreement on the recommended parameters and alternative views is shown. The rationale for the recommendations and the limitations of current evidence are discussed.

CONCLUSIONS:

Through this comprehensive review of available evidence and interactive exchange of vast experience by international experts, a guideline was developed to provide a practical reference for setting dose prioritization and acceptance criteria for tumor volumes and OARs. The final decision on the treatment prescription should be based on the individual clinical situation and the patient's acceptance of optimal balance of risk.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nasopharyngeal Neoplasms / Radiotherapy, Intensity-Modulated / Organs at Risk / Nasopharyngeal Carcinoma / International Cooperation Type of study: Etiology_studies / Guideline / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2019 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nasopharyngeal Neoplasms / Radiotherapy, Intensity-Modulated / Organs at Risk / Nasopharyngeal Carcinoma / International Cooperation Type of study: Etiology_studies / Guideline / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2019 Document type: Article Affiliation country: